Angioedema clinical trials
The registry lists 164 studies for Angioedema across more than 10 countries. 19 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-21.
Status
- Completed
- 120
- Recruiting
- 14
- Terminated
- 10
- Status unknown
- 5
- Withdrawn
- 5
- Not yet recruiting
- 3
Phase
- Phase 3
- 52
- Phase 2
- 37
- Phase 1
- 22
- Phase 4
- 7
Where
- United States
- 77
- Germany
- 47
- United Kingdom
- 34
- Canada
- 33
- Italy
- 31
- France
- 28
Who runs them
Shire (41) · BioCryst Pharmaceuticals (14) · Pharming Technologies B.V. (10) · CSL Behring (10) · Takeda (9) · University Hospital, Grenoble (7) · KalVista Pharmaceuticals, Ltd. (5) · Astria Therapeutics, Inc. (5)
Studies
Recruiting first, then most recently updated. Showing 50 of 164 — search for more.
- Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyRecruitingNCT07266805Phase 316 countries
- ScATtEred Rare Disease Biobanks: a Model of Sample/Data Collection With susTainablE and Shared CriteriaRecruitingNCT067822301 country
- Angioedema Biomarker Research StudyRecruitingNCT062106981 country
- EAP for Deucrictibant Immediate-releaseAvailableNCT07759141
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema AttacksRecruitingNCT06361537Phase 313 countries
- A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling by invitationNCT07204938Phase 318 countries
- A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT070012805 countries
- Deployment o the Multidisciplinary Prospective Cohort ImminentRecruitingNCT04334031Not applicable1 country
- Allergy and Immunology Natural History StudyRecruitingNCT055844881 country
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)RecruitingNCT070214951 country
- Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema PatientsRecruitingNCT07046806Phase 1/21 country
- Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory DiseasesRecruitingNCT059043011 country
- Lanadelumab in Long-term Prophylaxis of Acquired AngioedemaRecruitingNCT06818474Phase 41 country
- Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated AngioedemaRecruitingNCT047635771 country
- Suicide Ideation in Hereditary AngioedemaNot yet recruitingNCT06811467
- Safety and Efficacy of Conestat Alfa for ACE-Induced AngioedemaNot yet recruitingNCT06679426Phase 3
- Lanadelumab in Bradykinin AngioedemaRecruitingNCT045979441 country
- Identification and Characterization of Genetic Variants in Hereditary AngioedemaNot yet recruitingNCT058336201 country
- CLOUD-R HAE REGISTRYRecruitingNCT038459461 country
- A Single-Arm Exploratory Study of NatureU Histra Dissolve on Chronic Urticaria SymptomsCompletedNCT07611032Not applicable1 country
- A Study of Navenibart in Participants With Hereditary AngioedemaActive, not recruitingNCT06842823Phase 324 countries
- A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaCompletedNCT05695248Phase 1/26 countries
- Research of Biomarkers Associated With the Diagnosis and Severity of Bradykinin AngioedemaTerminatedNCT049636341 country
- Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous UrticariaCompletedNCT05936567Phase 23 countries
- Characterization of Rhythmicity Profiles of Bradykinin-mediated Angioedema Attacks Using a Tracking Smartphone Application.WithdrawnNCT05304091
- A Long-term Study of STAR-0215 in Participants With Hereditary AngioedemaActive, not recruitingNCT06007677Phase 27 countries
- A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedNCT05259917Phase 321 countries
- A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IICompletedNCT04208412Phase 210 countries
- A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedNCT04349800Phase 11 country
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT0139786413 countries
- OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)CompletedNCT05139810Phase 314 countries
- FIRAZYR General Drug Use-Results Survey (Japan)CompletedNCT040571311 country
- A Study to Explore Hereditary Angioedema (HAE) Symptoms and Treatment Patterns in Korean PeopleCompletedNCT065874641 country
- A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)CompletedNCT05460325Phase 31 country
- Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)CompletedNCT0103496914 countries
- A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at HomeCompletedNCT054896401 country
- A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in CanadaCompletedNCT055784171 country
- Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanCompletedNCT03873116Phase 31 country
- A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-InhibitorCompletedNCT04444895Phase 310 countries
- A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaActive, not recruitingNCT05121376Phase 1/23 countries
- Social Evaluated Cold Pressor Test in Hereditary Angioedema PatientsCompletedNCT064142521 country
- Autonomic Nervous System Profile in Hereditary AngioedemaCompletedNCT064088051 country
- Mepolizumab in Episodic Angioedema With EosinophiliaTerminatedNCT04128371Phase 21 country
- Patient Registry to Evaluate the Real-world Safety of Ruconest®CompletedNCT036971871 country
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 210 countries
- Treatment of Angiotensin Converting Enzyme Inhibitor-induced AngioedemaTerminatedNCT04679311Phase 21 country
- Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency DepartmentCompletedNCT060960771 country
- A Study of STAR-0215 in Healthy Adult ParticipantsCompletedNCT05477160Phase 11 country
- The Role of the Coagulation Pathways in Recurrent AngioedemaTerminatedNCT02892682Not applicable1 country
- A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)CompletedNCT04206605Phase 310 countries